Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

  • ID: 4521411
  • Report
  • Region: Global
  • 376 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Astellas Pharma Inc
  • Corium International Inc
  • HitGen LTD
  • MEDRx Co Ltd
  • P2D Bioscience
  • MORE

Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood. Currently, marketed drugs for cognitive impairment disorders act by slowing disease progression or treating symptoms.

The total number of products under development for CIAS, dementia, mild cognitive impairment and Alzheimer's disease is 33, 109, 35 and 645, respectively. Key companies operating in these pipelines include Eli Lilly and Co., Bristol-Myers Squibb, Pfizer and AstraZeneca.

The majority of products under development for these disorders are small molecules, due to their ability to cross the blood-brain barrier and their proven commercial success in this area. In addition, the majority of products are neuromodulators, impacting the dopaminergic, serotonergic and glutamatergic systems. There is diversity within each indication in terms of molecule type and molecular targets.

This report “Cognitive Impairment Disorders Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for cognitive impairment disorders. It comprehensively documents therapeutics under development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

Scope

  • Which companies are the most active within the pipeline for cognitive impairment disorders?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Astellas Pharma Inc
  • Corium International Inc
  • HitGen LTD
  • MEDRx Co Ltd
  • P2D Bioscience
  • MORE

1 Table of Contents

2 Introduction
2.1 Cognitive Impairment Disorders Report Coverage
2.2 Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
2.3 Dementia - Overview
2.4 Mild Cognitive Impairment - Overview
2.5 Alzheimer's Disease - Overview

3 Therapeutics Development
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS)
3.2 Dementia
3.3 Mild Cognitive Impairment
3.4 Alzheimer's Disease

4 Therapeutics Assessment
4.1 Cognitive Impairment Associated With Schizophrenia (CIAS)
4.2 Dementia
4.3 Mild Cognitive Impairment
4.4 Alzheimer's Disease

5 Companies Involved in Therapeutics Development
5.1 Cognitive Impairment Associated With Schizophrenia (CIAS)
5.2 Dementia
5.3 Mild Cognitive Impairment
5.4 Alzheimer's Disease

6 Dormant Projects
6.1 Cognitive Impairment Associated With Schizophrenia (CIAS)
6.2 Dementia
6.3 Mild Cognitive Impairment
6.4 Alzheimer's Disease

7 Discontinued Products
7.1 Cognitive Impairment Associated With Schizophrenia (CIAS)
7.2 Dementia
7.3 Mild Cognitive Impairment
7.4 Alzheimer's Disease

8 Product Development Milestones
8.1 Cognitive Impairment Associated With Schizophrenia (CIAS)
8.2 Dementia
8.3 Mild Cognitive Impairment
8.4 Alzheimer's Disease

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 3: Products under Development by Companies Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 4: Number of Products under Development for Dementia
Table 5: Number of Products under Development by Companies, Dementia
Table 6: Number of Products under Development by Universities/Institutes, Dementia
Table 7: Products under Development by Companies, Dementia
Table 8: Products under Development by Universities/Institutes, Dementia
Table 9: Number of Products under Development for Mild Cognitive Impairment
Table 10: Number of Products under Development by Companies, Mild Cognitive Impairment
Table 11: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment
Table 12: Products under Development by Companies, Mild Cognitive Impairment
Table 13: Products under Development by Universities/Institutes, Mild Cognitive Impairment
Table 14: Number of Products under Development for Alzheimer's Disease
Table 15: Number of Products under Development by Companies, Alzheimer's Disease
Table 16: Number of Products under Development by Universities/Institutes, Alzheimer's Disease
Table 17: Products under Development by Companies, Alzheimer's Disease
Table 18: Products under Development by Universities/Institutes, Alzheimer's Disease
Table 19: Number of Products by Stage and Target, Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 20: Number of Products by Stage and Mechanism of Action, Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 21: Number of Products by Stage and Route of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 22: Number of Products by Stage and Molecule Type, Cognitive Impairment Associated With Schizophrenia (CIAS)
Table 23: Number of Products by Stage and Target, Dementia
Table 24: Number of Products by Stage and Mechanism of Action, Dementia
Table 25: Number of Products by Stage and Route of Administration, Dementia
Table 26: Number of Products by Stage and Molecule Type, Dementia
Table 27: Number of Products by Stage and Target, Mild Cognitive Impairment
Table 28: Number of Products by Stage and Mechanism of Action, Mild Cognitive Impairment
Table 29: Number of Products by Stage and Route of Administration, Mild Cognitive Impairment
Table 30: Number of Products by Stage and Molecule Type, Mild Cognitive Impairment
Table 31: Number of Products by Stage and Target, Alzheimer's Disease
Table 32: Number of Products by Stage and Mechanism of Action, Alzheimer's Disease
Table 33: Number of Products by Stage and Route of Administration, Alzheimer's Disease
Table 34: Number of Products by Stage and Molecule Type, Alzheimer's Disease
Table 35: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc
Table 36: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc
Table 37: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co
Table 38: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics
Table 39: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd
Table 40: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co
Table 41: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd
Table 42: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck AS
Table 43: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Heptares Therapeutics Ltd
Table 44: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies Inc
Table 45: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL
Table 46: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc
Table 47: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sage Therapeutics Inc
Table 48: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB
Table 49: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL
Table 50: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd
Table 51: Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc
Table 52: Dementia - Pipeline by Acadia Pharmaceuticals Inc
Table 53: Dementia - Pipeline by Accera Inc
Table 54: Dementia - Pipeline by Acorda Therapeutics Inc
Table 55: Dementia - Pipeline by Actinogen Medical Ltd
Table 56: Dementia - Pipeline by Adamas Pharmaceuticals Inc
Table 57: Dementia - Pipeline by AgeneBio Inc
Table 58: Dementia - Pipeline by Alector LLC
Table 59: Dementia - Pipeline by Allergan Plc
Table 60: Dementia - Pipeline by Anavex Life Sciences Corp
Table 61: Dementia - Pipeline by Asceneuron SA
Table 62: Dementia - Pipeline by Axon Neuroscience SE
Table 63: Dementia - Pipeline by Axovant Sciences Ltd

List of Figures
Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 3: Number of Products under Development for Dementia
Figure 4: Number of Products under Development by Companies, Dementia
Figure 5: Number of Products under Development by Universities/Institutes, Dementia
Figure 6: Number of Products under Development for Mild Cognitive Impairment
Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment
Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment
Figure 9: Number of Products under Development for Alzheimer's Disease
Figure 10: Number of Products under Development by Companies, Alzheimer's Disease
Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer's Disease
Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)
Figure 20: Number of Products by Top 10 Targets, Dementia
Figure 21: Number of Products by Stage and Top 10 Targets, Dementia
Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia
Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia
Figure 24: Number of Products by Top 10 Routes of Administration, Dementia
Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia
Figure 26: Number of Products by Top 10 Molecule Types, Dementia
Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia
Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment
Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment
Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment
Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment
Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment
Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment
Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment
Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment
Figure 36: Number of Products by Top 10 Targets, Alzheimer's Disease
Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer's Disease
Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease
Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease
Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer's Disease
Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease
Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer's Disease
Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Accera Inc
  • Acorda Therapeutics Inc
  • Actinogen Medical Ltd
  • Acumen Pharmaceuticals Inc
  • Adamas Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • AFFiRiS AG
  • AgeneBio Inc
  • Alector LLC
  • Allergan Plc
  • Allgenesis Biotherapeutics Inc
  • Allinky Biopharma
  • ALSP Inc
  • Alzhyme Pty Ltd
  • Alzinova AB
  • AlzProtect SAS
  • Amarantus Bioscience Holdings Inc
  • Amgen Inc
  • Anavex Life Sciences Corp
  • Annexon Inc
  • Aphios Corp
  • Apodemus AB
  • Applied Research using OMIC Sciences SL
  • Aptevo Therapeutics Inc
  • Araclon Biotech SL
  • Archer Pharmaceuticals Inc
  • ArmaGen Inc
  • Asceneuron SA
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Aucta Pharmaceuticals LLC
  • Avineuro Pharmaceuticals Inc
  • Avraham Pharmaceuticals Ltd
  • Axon Neuroscience SE
  • Axovant Sciences Ltd
  • Axsome Therapeutics Inc
  • Axxam SpA
  • AZTherapies Inc
  • Beactica AB
  • Berg LLC
  • BioArctic AB
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioHealthonomics Inc
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • Bsim2
  • Cadent Therapeutics
  • Cantabio Pharmaceuticals Inc
  • Cardax Inc
  • Carna Biosciences Inc
  • Celon Pharma SA
  • CereSpir Inc
  • CHA Bio & Diostech Co Ltd
  • Clera Inc
  • Cognition Therapeutics Inc
  • Cognosci Inc
  • CohBar Inc
  • Connexios Life Sciences Pvt Ltd
  • ConSynance Therapeutics Inc
  • Corium International Inc
  • Coronis NeuroSciences Ltd
  • Cortice Biosciences Inc
  • Cotinga Pharmaceuticals Inc
  • Crossbeta Biosciences BV
  • Cypralis Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Daval International Ltd
  • Denali Therapeutics Inc
  • Diffusion Pharmaceuticals Inc
  • Dongkook Pharmaceutical Co Ltd
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • Echo Pharmaceuticals BV
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Endece LLC
  • Ensemble Therapeutics Corp
  • Epigen Biosciences Inc
  • Evotec AG
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc
  • Genervon Biopharmaceuticals LLC
  • Genzyme Corp
  • GlaxoSmithKline Plc
  • GliaCure Inc
  • Glialogix Inc
  • Golden Biotechnology Corp
  • Grifols SA
  • H. Lundbeck AS
  • Hemostemix Inc
  • Heptares Therapeutics Ltd
  • HitGen LTD
  • Hyundai Pharmaceutical Co Ltd
  • ICB International Inc
  • Ichor Medical Systems Inc
  • Icure Pharmaceutical Inc
  • ID Pharma Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Immungenetics AG
  • Immunwork Inc
  • Impel NeuroPharma Inc
  • India Globalization Capital Inc
  • Insys Therapeutics Inc
  • IntelGenx Corp
  • Intellect Neurosciences Inc
  • Intra-Cellular Therapies Inc
  • Io Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Iproteos SL
  • IRLAB Therapeutics AB
  • Ironwood Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Karuna Pharmaceuticals Inc
  • Krenitsky Pharmaceuticals Inc
  • K-Stemcell Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Lipopharma Therapeutics SL
  • Living Cell Technologies Ltd
  • Lupin Ltd
  • M3 Biotechnology Inc
  • ManRos Therapeutics
  • MedDay SA
  • Medesis Pharma SA
  • MedImmune LLC
  • MediPost Co Ltd
  • MEDRx Co Ltd
  • MEI Pharma Inc
  • Merck & Co Inc
  • Microlin Bio Inc
  • MindImmune Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • ModGene Pharma LLC
  • Montisera Ltd
  • NAL Pharmaceuticals Ltd
  • Nanomerics Ltd
  • NeoNeuro SAS
  • Neuraltus Pharmaceuticals Inc
  • Neurim Pharmaceuticals Ltd
  • Neurimmune Holding AG
  • Neuro Bio Ltd
  • NeuroGenetic Pharmaceuticals Inc
  • Neuron Biopharma SA
  • NeuroNascent Inc
  • NeurOp Inc
  • Neuropore Therapies Inc
  • Neuro-Sys SAS
  • Neurotez Inc
  • New World Laboratories Inc
  • NoNO Inc
  • Novartis AG
  • Nymox Pharmaceutical Corp
  • Octapharma AG
  • Oryzon Genomics SA
  • Otsuka Holdings Co Ltd
  • Ovensa Inc
  • Oxstem Ltd
  • P2D Bioscience
  • Pacific Northwest Biotechnology LLC
  • Pain Therapeutics Inc
  • Peptron Inc
  • Pfizer Inc
  • Pharmasum Therapeutics AS
  • Pharmaxis Ltd
  • Pharnext SA
  • Phoenix Biotechnology Inc
  • Prana Biotechnology Ltd
  • Prevacus Inc
  • Priavoid GmbH
  • Probiodrug AG
  • Progenra Inc
  • ProMIS Neurosciences Inc
  • ProQR Therapeutics NV
  • Proteome Sciences Plc
  • Proteostasis Therapeutics Inc
  • Sage Therapeutics Inc
  • Saniona AB
  • SBI Pharmaceuticals Co Ltd
  • Sinil Pharmaceutical Co Ltd
  • Spherium Biomed SL
  • Stemedica Cell Technologies Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Suven Life Sciences Ltd
  • Takeda Pharmaceutical Co Ltd
  • TauRx Therapeutics Ltd
  • Theranexus SAS
  • Therapix Biosciences Ltd
  • Vanda Pharmaceuticals Inc
  • Vicore Pharma AB
  • Voyager Therapeutics Inc
  • WAVE Life Sciences Ltd
  • WhanIn Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll